[Evaluation of physical development in children with classical phenylketonuria]

Voprosy Pitaniia
|February 5, 2016
PubMed

Insights

Modern infant formulas for phenylketonuria (PKU) improve physical development. Early treatment with phenylalanine-free amino acid mixtures supports healthy growth in children with PKU, unlike older protein hydrolysate formulas.

Area of Science:

  • Biochemistry
  • Pediatrics
  • Genetics

Context:

  • Phenylketonuria (PKU) is an inherited metabolic disorder affecting phenylalanine metabolism.
  • Dietary management, specifically a low-phenylalanine diet, is crucial for PKU patients.
  • Long-term protein restriction can impede growth and physical development in PKU individuals.

Purpose:

  • To assess the physical development of classical PKU patients at birth and during dietary treatment.
  • To compare the impact of different phenylalanine-free diet compositions on PKU patient growth.
  • To evaluate the effectiveness of modern amino acid mixtures versus older protein hydrolysates.

Summary:

  • A study analyzed 257 PKU patients using WHO Anthroplus 2009, comparing growth outcomes between those on protein hydrolysates (1980-1993) and amino acid mixtures (1995-2012).
  • Initial BMI Z-scores were comparable, but after 6 months, patients on modern amino acid mixtures showed significantly higher normal BMI Z-scores (95.6%) versus those on protein hydrolysates (71.3%).
  • Modern phenylalanine-free amino acid mixtures, enriched with essential nutrients, promote normal physical development in PKU patients.

Impact:

  • Highlights the importance of nutrient-enriched, phenylalanine-free formulas for optimal PKU management.
  • Suggests a shift towards contemporary amino acid-based diets for improved pediatric growth outcomes in PKU.
  • Provides evidence for enhanced physical development in PKU patients using advanced dietary interventions.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
327
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.6K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
693
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Pedigree Analysis01:35

Pedigree Analysis

Overview
90.7K